Akèy › Kansè tete negatif triple › Michigan
Etid klinik pou Kansè tete negatif triple nan Michigan
29 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06799065Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- University of Michigan ( Site 0103), Ann Arbor
- Henry Ford Health ( Site 0010), Detroit
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04585750Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 10, 2026 · NCT07652242Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
- William Beaumont Hospital, Royal Oak
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06465069Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Trinity Health, Ann Arbor
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT06270706Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- BAMF Health, Grand Rapids
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06562192A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Midwest, LLC, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07318805A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07503808BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT05768932I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Herbert-Herman Cancer Center, Sparrow Hospital, Lansing
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Henry Ford Health System, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 9, 2026 · NCT05490472A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Michigan, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT05902988A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2025 · NCT05086692CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Trinity Health-Michigan, Ypsilanti
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jan 7, 2025 · NCT06230185Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.